Pfizer, Anumana team up to develop AI algorithm for cardiac amyloidosis detection
Related Articles
J&J Hired Thousands of Data Scientists. Will The Strategy Pay Off?
WSJ: One project—with the Mayo Clinic and a health-technology company called Anumana based in Cambridge, Mass.—aims to speed up diagnosis of high blood pressure in the lungs, or pulmonary hypertension.…{post_date: F d, Y}
Anumana Secures FDA Clearance for First-of-Its-Kind ECG-AI Algorithm for Early Detection of Pulmonary Hypertension
CAMBRIDGE, Mass. – March 28, 2026 – Anumana, a leader in cardiovascular AI, has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its pulmonary hypertension (PH) algorithm, an AI-enabled…{post_date: F d, Y}
How a New AI Algorithm Could Help in the Early Detection of Heart Disease
Xtalks: An AI algorithm developed by researchers at the Mayo Clinic through its newly formed health technology company Anumana Inc., can assess for low ejection fraction through routine electrocardiograms (ECG,…{post_date: F d, Y}
Anumana Announces Issuance of New American Medical Association CPT Category III Codes for Novel ECG AI Analysis of Cardiac Dysfunction
DAIC: Anumana, Inc., an AI-driven health technology company from nference, Inc., today announced the American Medical Association (AMA) has issued new industry-first Category III Current Procedural Terminology (CPT) codes for…{post_date: F d, Y}